A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

NCT03957681 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Systemic Sclerosis

Interventions

DRUG: KHK4827
DRUG: Placebo

Sponsor

Kyowa Kirin Co., Ltd.